Drug intelligence / Profile preview

secnidazole + ciprofloxacin

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral, Intravenous, Ophthalmic, Otic
01

Overview

Secnidazole + ciprofloxacin is a combination of two small molecule antibiotics used to treat infections caused by susceptible bacteria and protozoa. Secnidazole is a 5-nitroimidazole antimicrobial that acts primarily against anaerobic bacteria and certain protozoa by generating reactive intermediates that damage DNA and disrupt protein synthesis, leading to cell death[3][2]. Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination[6]. This combination may be considered in the management of mixed infections or syndromic treatment approaches such as pelvic inflammatory disease when both anaerobic coverage (secnidazole) and broad-spectrum Gram-negative/Gram-positive coverage (ciprofloxacin) are needed[5]. Each drug has distinct mechanisms of action but together provide complementary antimicrobial activity.

02

Targets

NTR (Bacterial nitroreductase)DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on secnidazole + ciprofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on secnidazole + ciprofloxacin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call